LOPETUSO, Loris Riccardo
 Distribuzione geografica
Continente #
NA - Nord America 2.723
EU - Europa 1.452
AS - Asia 949
SA - Sud America 118
AF - Africa 16
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 6
Totale 5.271
Nazione #
US - Stati Uniti d'America 2.685
SG - Singapore 599
IE - Irlanda 476
IT - Italia 340
SE - Svezia 265
CN - Cina 110
RU - Federazione Russa 108
BR - Brasile 103
VN - Vietnam 95
DE - Germania 67
HK - Hong Kong 37
GB - Regno Unito 33
AT - Austria 31
IN - India 26
CA - Canada 24
BE - Belgio 16
FI - Finlandia 16
RO - Romania 16
TW - Taiwan 16
IR - Iran 13
FR - Francia 12
NL - Olanda 12
MX - Messico 11
TH - Thailandia 11
BG - Bulgaria 9
PL - Polonia 8
UA - Ucraina 7
EG - Egitto 6
JP - Giappone 6
AU - Australia 5
ES - Italia 5
EU - Europa 5
HR - Croazia 5
LU - Lussemburgo 5
PK - Pakistan 5
TR - Turchia 5
AR - Argentina 4
BD - Bangladesh 4
CH - Svizzera 4
LT - Lituania 4
MY - Malesia 4
DK - Danimarca 3
EC - Ecuador 3
IQ - Iraq 3
KR - Corea 3
VE - Venezuela 3
ZA - Sudafrica 3
CO - Colombia 2
ID - Indonesia 2
ME - Montenegro 2
NO - Norvegia 2
PA - Panama 2
SA - Arabia Saudita 2
SC - Seychelles 2
TN - Tunisia 2
UY - Uruguay 2
UZ - Uzbekistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
DO - Repubblica Dominicana 1
HU - Ungheria 1
IM - Isola di Man 1
KE - Kenya 1
KG - Kirghizistan 1
MA - Marocco 1
MT - Malta 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PY - Paraguay 1
QA - Qatar 1
RS - Serbia 1
Totale 5.271
Città #
Chandler 766
Dublin 476
Singapore 378
Princeton 234
Jacksonville 190
Ashburn 173
Altamura 114
Dong Ket 93
Wilmington 85
Santa Clara 76
Ann Arbor 57
Los Angeles 44
Chieti 42
The Dalles 42
Rome 33
Hong Kong 31
Pescara 30
Nuremberg 29
Falls Church 27
Taranto 19
Norwalk 17
Brussels 16
Teramo 16
London 15
Munich 12
New York 12
Pune 12
Xitun 11
Cluj-Napoca 10
Guangzhou 10
Edinburgh 9
Moscow 9
Vienna 9
Helsinki 8
Sofia 8
Washington 8
Frankfurt am Main 7
São Paulo 7
Toronto 7
Chicago 6
Guglionesi 6
Tehran 6
Bangkok 5
Belo Horizonte 5
Bologna 5
Chiang Mai 5
Dallas 5
Milan 5
San Jose 5
Seattle 5
Stockholm 5
Stoke-on-Trent 5
Woodbridge 5
Atlanta 4
Bari 4
Beijing 4
Boardman 4
Hangzhou 4
Kuala Lumpur 4
Lappeenranta 4
Shanghai 4
Tokyo 4
Ankara 3
Brasília 3
Copenhagen 3
Hefei 3
Kunming 3
Luxembourg 3
Montale 3
Montreal 3
Multan 3
Rio de Janeiro 3
São Bernardo do Campo 3
Taipei 3
Termoli 3
Turku 3
Zagreb 3
Zurich 3
Alexander 2
Amsterdam 2
Andover 2
Baghdad 2
Bengaluru 2
Cairo 2
Central 2
Cologne 2
Corvallis 2
Croydon 2
Dhaka 2
Echt 2
Fairfield 2
Fremont 2
Greccio 2
Guadalajara 2
Hamburg 2
Handan 2
Houston 2
Hyderabad 2
Jati 2
Jeddah 2
Totale 3.343
Nome #
Assessment of crohn’s disease activity: Magnetic resonance enterography in comparison with clinical and endoscopic evaluations 113
13C-octanoic acid breath test to study gastric emptying time 99
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): Preliminary results from a retrospective cohort study 98
Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease 89
Anti-tumor necrosis factor α therapy associates to type 17 helper T lymphocytes immunological shift and significant microbial changes in dextran sodium sulphate colitis 88
Akkermansia muciniphila: Key player in metabolic and gastrointestinal disorders 77
Bacillus clausii and gut homeostasis: state of the art and future perspectives 70
Specific 13C functional pathways as diagnostic targets in gastroenterology breath-tests: tricks for a correct interpretation 70
Characterization of sarcopenia in an IBD population attending an Italian gastroenterology tertiary center 67
Proteobacteria: A common factor in human diseases 64
Role of yeasts in healthy and impaired gut microbiota: The gut mycome 62
Esophageal microbiome signature in patients with Barrett’s esophagus and esophageal adenocarcinoma 62
The gastrointestinal microbiome - Functional interference between stomach and intestine 62
Gut microbiota profiling and gut-brain crosstalk in children affected by pediatric acute-onset neuropsychiatric syndrome and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections 62
Bacillus clausii for the treatment of acute diarrhea in children: A systematic review and meta-analysis of randomized controlled trials 61
Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of Akkermansia muciniphila 61
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab 61
Role of Helicobacter pylori infection on nutrition and metabolism 60
Commensal Clostridia: Leading players in the maintenance of gut homeostasis 60
Tricks for interpreting and making a good report on hydrogen and 13C breath tests 59
Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide 59
Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease 59
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 59
High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. Pylori infection 58
Ulcerative colitis 57
Food components and dietary habits: Keys for a healthy gut microbiota composition 57
European Crohn's and colitis organisation topical review on treatment withdrawal ['exit strategies'] in inflammatory bowel disease 57
Actinobacteria: A relevant minority for the maintenance of gut homeostasis 57
Gut microbiota and inflammatory bowel disease: So far so gut! 56
The innate and adaptive immune system as targets for biologic therapies in inflammatory bowel disease 56
The gut barrier: New acquisitions and therapeutic approaches 55
Locally injected Infliximab ameliorates murine DSS colitis: Differences in serum and intestinal levels of drug between healthy and colitic mice 55
Flexible colonoscopy in mice to evaluate the severity of colitis and colorectal tumors using a validated endoscopic scoring system 55
Dietary magnesium alleviates experimental murine colitis through upregulation of the transient receptor potential melastatin 6 channel 55
A modern multidisciplinary approach to the treatment of enterocutaneous fistulas in Crohn’s disease patients 55
Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection—single versus multiple infusions 54
Bacteriocins and bacteriophages: Therapeutic weapons for gastrointestinal diseases? 54
Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises from a First Meta-Analysis 54
Commentary to “safety, clinical response, and microbiome findings following fecal microbiota transplant in children with inflammatory bowel disease” 53
Microbiota and inflammatory bowel disease: An update 53
IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair 53
Prevalence of cervical HPV and attitude towards cervical screening in IBD patients under immunomodulatory treatment: A multidisciplinary management experience 52
Gut Virome and Inflammatory Bowel Disease 52
Opposing functions of classic and novel IL-1 family members in gut health and disease 52
Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders 52
Gut microbiota modulation and mucosal immunity: Focus on Rifaximin 51
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action 51
Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome? 51
The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications 51
A novel model of colitis-associated cancer in SAMP1/YitFc mice with Crohn's disease-like ileitis 50
Liver Injury, Endotoxemia, and Their Relationship to Intestinal Microbiota Composition in Alcohol-Preferring Rats 50
Considering gut microbiota disturbance in the management of Helicobacter pylori infection 50
Gelatin tannate and tyndallized probiotics: a novel approach for treatment of diarrhea 50
Gelatin tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating gut microbiota composition: Emerging role for ‘gut barrier protectors’ in IBD? 49
Infliximab does not increase colonic cancer risk associated to murine chronic colitis 49
Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF-a treatment 49
Beyond the HLA Genes in Gluten-Related Disorders 49
Anti-TNF-α-induced psoriasiform lesions in IBD: An abnormal immune activation or a 'patchy cutaneous' immune suppression? 49
Relationship between oral microbiota and periodontal disease: A systematic review 48
Pre- and posttherapy assessment of intestinal soluble mediators in IBD: Where we stand and future perspectives 48
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 48
Epidemiology of inflammatory bowel disease in the Republic of San Marino: The “EPIMICI – San Marino” study 48
Intestinal permeability in physiological and pathological conditions: Major determinants and assessment modalities 47
Human herpesvirus 8-associated colonic Kaposi's sarcoma during vedolizumab treatment in ulcerative colitis: A case report and review of the literature 47
The use of anti-spasmodics in the treatment of irritable bowel syndrome: Focus on otilonium bromide 47
The “dica” endoscopic classification for diverticular disease of the colon shows a significant interobserver agreement among community endoscopists 47
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin 47
Prevalence of severe irritable bowel syndrome among Italian adults. A meta-analysis 46
Epidemiological evaluation of acute gastroenteritis and therapeutic approaches in Middle East Countries 46
The therapeutic management of gut barrier leaking: The emerging role for mucosal barrier protectors 46
Assessment of neurological manifestations in hospitalized patients with COVID-19 46
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 46
Microparticles produced by activated platelets carry a potent and functionally active angiogenic signal in subjects with crohn’s disease 45
Can we predict the efficacy of anti-TNF-α agents? 45
Epithelial-specific Toll-like Receptor (TLR)5 Activation Mediates Barrier Dysfunction in Experimental Ileitis 43
Microbes and Alzheimer' disease: Lessons from H. Pylori and GUT microbiota 43
Coeliac disease under a microscope: Histological diagnostic features and confounding factors 43
Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis 42
Fighting the Hype for Predictors of Efficacy in Inflammatory Bowel Disease 41
Bariatric procedures and microbiota: patient selection and outcome prediction 41
Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update 40
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications 40
Fecal transplantation for ulcerative colitis: current evidence and future applications 39
Gut microbial flora, prebiotics, and probiotics in IBD: Their current usage and utility 39
Coordinated Multi-Language Translation of A Validated Symptom Questionnaire for Carbohydrate Intolerances: A Practical Structured Procedure 38
Intestinal gas production and gastrointestinal symptoms: from pathogenesis to clinical implication 38
Exploring Bacteroidetes: Metabolic key points and immunological tricks of our gut commensals 38
The use of probiotics in different phases of diverticular disease 37
Skeletal muscle-gut axis: Emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases 37
Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation 37
International consensus conference on stool banking for faecal microbiota transplantation in clinical practice 35
Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver 33
The impact of COVID-19 pandemic on IBD endoscopic procedures in a high-volume IBD Center 33
The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease 32
European guideline on indications, performance, and clinical impact of hydrogen and methane breath tests in adult and pediatric patients: European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Neurogastroenterology and Motility, and European Society for Paediatric Gastroenterology Hepatology and Nutrition consensus 31
Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study 30
How to face the advent of sars-cov-2 vaccination in ibd patients: Another task for gastroenterologists 30
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 30
Increased Faecalibacterium abundance is associated with clinical improvement in patients receiving rifaximin treatment 29
Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection: An update 29
Totale 5.168
Categoria #
all - tutte 34.297
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.297


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021782 235 4 165 34 59 135 12 10 10 6 16 96
2021/2022705 53 3 3 118 20 16 11 28 54 39 60 300
2022/20231.882 241 337 89 224 95 348 120 143 169 18 81 17
2023/2024849 53 36 47 51 36 186 235 87 14 37 13 54
2024/20251.548 158 348 191 54 36 112 82 96 305 84 82 0
Totale 5.766